Role of aberrant PI3K pathway activation in gallbladder tumorigenesis

被引:49
|
作者
Lunardi, Andrea [1 ]
Webster, Kaitlyn A. [1 ]
Papa, Antonella [1 ]
Padmani, Bhavik [2 ]
Clohessy, John G. [2 ]
Bronson, Roderick T. [3 ]
Pandolfi, Pier Paolo [1 ]
机构
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Canc Res Inst,Beth Israel Deaconess Canc Ctr,Dept, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Preclin Murine Pharmacogenet Facil, Boston, MA 02215 USA
[3] Dana Farber Harvard Comprehens Canc Ctr, Boston, MA USA
关键词
PI3K; PTEN; gallbladder tumorigenesis; mouse model; BILIARY-TRACT; PTEN; MUTATIONS;
D O I
10.18632/oncotarget.1808
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The PI3K/AKT pathway governs a plethora of cellular processes, including cell growth, proliferation, and metabolism, in response to growth factors and cytokines. By acting as a unique lipid phosphatase converting phosphatidylinositol-3,4,5,-trisphosphate (PIP3) to phosphatidylinositol-4,5,-bisphosphate (PIP2), phosphatase and tensin homolog (PTEN) acts as the major cellular suppressor of PI3K signaling and AKT activation. Recently, PI3K mutations and loss/mutation of PTEN have been characterized in human gallbladder tumors; whether aberrant PTEN/PI3K pathway plays a causal role in gallbladder carcinogenesis, however, remains unknown. Herein we show that in mice, deregulation of PI3K/AKT signaling is sufficient to transform gallbladder epithelial cells and trigger fully penetrant, highly proliferative gallbladder tumors characterized by high levels of phospho-AKT. Histopathologically, these mouse tumors faithfully resemble human adenomatous gallbladder lesions. The identification of PI3K pathway deregulation as both an early event in the neoplastic transformation of the gallbladder epithelium and a main mechanism of tumor growth in Pten heterozygous and Pten mutant mouse models provides a new framework for studying in vivo the efficacy of target therapies directed against the PI3K pathway, as advanced metastatic tumors are often addicted to "trunkular" mutations.
引用
收藏
页码:894 / 900
页数:7
相关论文
共 50 条
  • [1] The role of PI3K/AKT signaling pathway in gallbladder carcinoma
    Wu, Zeyu
    Yu, Xiao
    Zhang, Shuijun
    He, Yuting
    Guo, Wenzhi
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2022, 14 (07): : 4426 - 4442
  • [2] The PI3K/mTOR Pathway in Gallbladder Carcinoma
    Primiani, A.
    Shahid, M.
    Yilmaz, O.
    Ferrone, C. R.
    Borger, D. R.
    Iafrate, A. J.
    Zhu, A. X.
    Deshpande, V.
    LABORATORY INVESTIGATION, 2013, 93 : 173A - 173A
  • [3] The PI3K/mTOR Pathway in Gallbladder Carcinoma
    Primiani, A.
    Shahid, M.
    Yilmaz, O.
    Ferrone, C. R.
    Borger, D. R.
    Iafrate, A. J.
    Zhu, A. X.
    Deshpande, V.
    MODERN PATHOLOGY, 2013, 26 : 173A - 173A
  • [4] Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML
    O Lindblad
    E Cordero
    A Puissant
    L Macaulay
    A Ramos
    N N Kabir
    J Sun
    J Vallon-Christersson
    K Haraldsson
    M T Hemann
    Å Borg
    F Levander
    K Stegmaier
    K Pietras
    L Rönnstrand
    J U Kazi
    Oncogene, 2016, 35 : 5119 - 5131
  • [5] Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML
    Lindblad, O.
    Cordero, E.
    Puissant, A.
    Macaulay, L.
    Ramos, A.
    Kabir, N. N.
    Sun, J.
    Vallon-Christersson, J.
    Haraldsson, K.
    Hemann, M. T.
    Borg, A.
    Levander, F.
    Stegmaier, K.
    Pietras, K.
    Ronnstrand, L.
    Kazi, J. U.
    ONCOGENE, 2016, 35 (39) : 5119 - 5131
  • [6] Aberrant Activation of the PI3K/mTOR Pathway Promotes Resistance to Sorafenib in AML
    Lindblad, Oscar
    Cordero, Eugenio
    Puissant, Alexandre
    Macaulay, Lucy
    Kabir, Nuzhat N.
    Sun, Jianmin
    Haraldsson, Karin
    Borg, Ake
    Levander, Fredrik
    Stegmaier, Kimberly
    Pietras, Kristian
    Ronnstrand, Lars
    Kazi, Julhash U.
    BLOOD, 2015, 126 (23)
  • [7] Frequent Aberrant Activation of the PI3K/Akt/mTOR Pathway in Pancreatic Endocrine Tumors
    Zhou, X. P.
    Frankel, W. L.
    Bloomston, M.
    Iwenofu, O. H.
    Bellizzi, A. M.
    LABORATORY INVESTIGATION, 2009, 89 : 327A - 327A
  • [8] Frequent Aberrant Activation of the PI3K/Akt/mTOR Pathway in Pancreatic Endocrine Tumors
    Zhou, X. P.
    Frankel, W. L.
    Bloomston, M.
    Iwenofu, O. H.
    Bellizzi, A. M.
    MODERN PATHOLOGY, 2009, 22 : 327A - 327A
  • [9] Activation of the PI3K/Akt pathway in neuroblastoma
    Sartelet, Herve
    Castaing, Marine
    Fabre, Monique
    Bosq, Jacques
    Rougemont, Anne-Laure
    Michieis, Stefan
    Vassal, Gilles
    VIRCHOWS ARCHIV, 2007, 451 (02) : 130 - 130
  • [10] Activation of the PI3K/Akt pathway in neuroblastoma
    Sartelet, H.
    Castain, M.
    Fabre, M.
    Bosq, J.
    Rougemont, A.
    Michiels, S.
    Vassal, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)